MedTrace Logo

Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections

NCT05988177 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-08-14

No results posted yet for this study

Summary

This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

Conditions

  • Carbapenem Resistant Bacterial Infection
  • Hemophagocytic Lymphohistiocytoses

Interventions

DRUG

Carrimycin tablets

Carrimycin tablets are administered 400mg a day orally for 7 days.

Sponsors & Collaborators

  • Beijing Friendship Hospital

    lead OTHER

Principal Investigators

  • Zhao Wang, MD · Beijing Friendship Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-30
Primary Completion
2026-08-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05988177 on ClinicalTrials.gov